• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of cancer care >Application of peripherally inserted central catheter in acute myeloid leukaemia patients undergoing induction chemotherapy
【24h】

Application of peripherally inserted central catheter in acute myeloid leukaemia patients undergoing induction chemotherapy

机译：外周插入中央导管在急性髓性白血病患者接受诱导化疗中的应用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Increasingly, peripherally inserted central catheters ( PICC ) are applied in patients with haematological malignancies. The feasibility and safety of PICC for induction chemotherapy in acute myeloid leukaemia ( AML ) remain unclear. Medical records of 89 newly diagnosed adult de novo AML patients, who achieved complete remission, were retrospectively reviewed ( PICC group, n ?=?43; intravenous [ IV ] line group, n ?=?46). Patients' clinical characteristics and the number of blind punctures for blood sampling were compared between these two groups, and risk factors associated with bacteraemia were identified by univariate analysis. Patients in the PICC group experienced significantly fewer blind punctures than those in the IV line group (3.3?±?3.6 vs. 14.4?±?6.0; p ?=?.000); 20.9% of PICC patients had bacteraemia, compared with 23.9% in the IV line group ( p ?=?.803). Most patients (76.7%) removed their PICC because treatment was completed. PICC increased the quality of life in AML patients undergoing chemotherapy induction by reducing the number of blind blood punctures required. Bacteraemia in PICC patients was comparable to that in IV line patients. PICC is, therefore, a feasible and safe central venous device for use in AML patients.
机译：越来越多地插入的中央导管（PICC）用于血液恶性肿瘤患者。 PICC在急性髓性白血病（AML）中感应化疗的可行性和安全性仍不清楚。回顾性审查了89名新诊断的成人De Novo AML患者，达到完全缓解的患者（PICC组，N？43;静脉注射[IV]线组，N？=？46）。在这两组之间比较了患者的临床特征和血液取样的盲穿刺的数量，并且通过单变量分析确定与细菌血症相关的危险因素。 PICC集团的患者比IV线组中的盲目较少（3.3？±3.6与14.4？±6.0; p？= ?. 000）; 20.9％的PICC患者患有细菌血症，而IV线组（P？=〜803）。大多数患者（76.7％）取消了他们的PICC，因为治疗完成。 PICC通过减少所需的盲目血液穿孔的数量来提高AML患者的生活质量。 PICC患者的菌血症与IV线患者的含量相当。因此，PICC是可行和安全的中央静脉装置，用于AML患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号